CompletedPhase 2NCT04492618
Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica
Studying Necrobiosis lipoidica
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Aaron R. Mangold
- Principal Investigator
- Aaron R Mangold, M.DMayo Clinic
- Intervention
- Ruxolitinib(drug)
- Enrollment
- 12 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2022
Study locations (1)
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04492618 on ClinicalTrials.gov